Phototherapy for the treatment of cutaneous graft‐versus‐host disease: A systematic review
Photodermatology, Photoimmunology & Photomedicine · 2024
DOI: 10.1111/phpp.12997 ↗At a glance
Systematische Übersicht in Photodermatology, Photoimmunology & Photomedicine, 2024. Written by Tahel Fachler-Sharp and 6 co-authors. Institution: Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel. Major MEDLINE topics: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Cited 9 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Cutaneous graft‐versus‐host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation. Phototherapy has been used to treat cutaneous GVHD, but data on its safety and efficacy are sparse.
Aim
Review the current medical literature regarding the efficacy, dosing, and safety of various types of phototherapies for the treatment of cutaneous GVHD.
Methods
A systematic review of PubMed, Embase, Cochrane, and ClinicalTrials databases was performed. Publications were screened according to the PRISMA guidelines. Exclusion criteria comprised case reports and case series reporting less than five patients, review articles, and articles not published in English.
Results
A total of 28/1304 (2.5%) studies were included. Fifteen studies ( n = 267 patients) focused on psoralen and ultraviolet (UV) A (PUVA), in which 65.5% of patients received concomitantly other systemic treatments. The response rate was 89.9%, with a mean of 33.2 treatments. Adverse events were recorded in 54% but were mainly mild. Eight studies, encompassing 95 patients, focused on narrow‐band (NB) UVB. A response was observed in 94%, with a mean number of 26 treatments and 8.6% adverse effects. UVA1 was reported in six studies ( n = 132 patients). A response was recorded in 89.3% with a mean of 26.2 treatments. Adverse events were noted in 70.1%, with a discontinuation rate of 10.9%. It should be noted that adverse events were recorded during the follow‐up period of the studies, which varied significantly, ranging from no follow‐up to 31 months.
Conclusions
Current data regarding the use of phototherapy for the treatment of cutaneous GVHD are based on retrospective studies and case series. The present report advocates the use of one of the three modalities of phototherapy as an effective and safe adjunctive treatment for cutaneous GVHD, especially NB UVB phototherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
- Department of Obstetrics and Gynecology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
- Service of Plastic Surgery, Assuta Ashdod Medical Center, Ashdod, Israel.
ORCID profiles: Rony Shreberk-Hassidim
Cite
APA
Fachler-Sharp, T., Kobal, I., Sheffer-Levi, S., Cohen, A., Hassidim, A., Molho-Pessach, V., & Shreberk-Hassidim, R. (2024). Phototherapy for the treatment of cutaneous graft‐versus‐host disease: A systematic review. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.12997
Vancouver
Fachler-Sharp T, Kobal I, Sheffer-Levi S, Cohen A, Hassidim A, Molho-Pessach V, et al. Phototherapy for the treatment of cutaneous graft‐versus‐host disease: A systematic review. Photodermatology, Photoimmunology & Photomedicine. 2024. doi:10.1111/phpp.12997
BibTeX
@article{FachlerSharp2024,
author = {Fachler-Sharp, Tahel and Kobal, Inbar and Sheffer-Levi, Sivan and Cohen, Adiel and Hassidim, Ayal and Molho-Pessach, Vered and Shreberk-Hassidim, Rony},
title = {Phototherapy for the treatment of cutaneous graft‐versus‐host disease: A systematic review},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2024},
doi = {10.1111/phpp.12997}
}
EUVIMED